Kyverna Therapeutics — Biomedical Watch V2

Traitements7programmes

Essais4liés

Publications3liées

SourceDBlocale

Traitements

7

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
KYV-101The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years.	Lupus, Myasthénie	Phase 2/3	Immunomodulation + Thérapie cellulaire	United States, Australia, Brazil, Germany, Saudi Arabia, United Kingdom	À vérifier
KYV-101 anti-CD19 CAR-T cell therapyA Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis	Lupus	Phase 1/2	Thérapie cellulaire	Germany	À vérifier
Standard lymphodepletion regimenA Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis	Lupus, Myasthénie	Phase 1/2	Thérapie cellulaire + Immunomodulation	Germany	À vérifier
KYV-101The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years.	Lupus	Phase 1	Immunomodulation + Thérapie cellulaire	United States	À vérifier
Standard lymphodepletion regimenA Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis	Myasthénie	Phase 2/3	Thérapie cellulaire + Immunomodulation	United States, Australia, Brazil, Germany, Saudi Arabia, United Kingdom	À vérifier
KYV-101 anti-CD19 CAR-T cell therapyA Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis	Lupus	Phase 1/2	Thérapie cellulaire	United States	À vérifier
KYV-101 anti-CD19 CAR-T cell therapyA Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis	Lupus	Phase 1/2	Thérapie cellulaire	Germany	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
KYV-101 anti-CD19 CAR-T cell therapy	Lupus	Phase 1/2	NCT06342960	KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis	TERMINATED
KYV-101 anti-CD19 CAR-T cell therapy	Lupus	Phase 1/2	NCT05938725	KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis	TERMINATED
Standard lymphodepletion regimen	Myasthénie	Phase 2/3	NCT06193889	KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis	RECRUITING
KYV-101	Lupus	Phase 1	NCT06152172	CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101	ACTIVE_NOT_RECRUITING

Publications

3

Molécule	Indication / population	Titre	Journal	Date
KYV-101		CAR-engineered cell therapies: current understandings and future perspectives.	Molecular biomedicine
KYV-101		Neutrophil transcriptomics in SLE reveals intrinsic disease signatures, shared ex vivo adaptation, and transcriptional reset after CAR T-cell therapy.	Annals of the rheumatic diseases
KYV-101		A new therapeutic frontier: CD19-targeting CAR-T cell therapy in rheumatoid arthritis: a concise report.	Rheumatology (Oxford, England)